GlassScriptPhysician profile
Harvey L Levy
NPI 1972593150
$48,692.63
in general payments reported to CMS, 2019-2025
6 companies · $4,700 in 2025
The $4,700 reported for 2025 was more than what 86% of Clinical Biochemical Genetics providers received nationally (typical 2025 total: $237).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,827 · 2020: $11K · 2021: $7,476 · 2022: $5,285 · 2023: $13K · 2025: $4,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $4,235 · Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,212.00 |
| Travel and Lodging | $4,235.26 |
| Food and Beverage | $637.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $16,272.00 | 2020-2023 | |
| Ptc Therapeutics, INC. | $12,671.89 | 2020-2025 | |
| Travere Therapeutics, INC. | $10,751.93 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $5,909.10 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $2,387.71 | 2019-2022 | |
| Amicus Therapeutics, INC. | $700.00 | 2025 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.